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The Opioid Epidemic: A Practice and 
Policy Perspective
Introduction
Today I will be talking about the escalating opioid epidemic and 
some innovative solutions my colleagues and I at Yale University 
and throughout the state of Connecticut, are working on to 
mitigate the consequences of this public health crisis. According to 
the recent data released from The National Survey on Drug Use and 
Health, 20.1 million Americans age 12 and over reported having a 
substance use disorder; two million specifically related to opioid 
use disorders in 2016. A total of 11.8 million people aged 12 or 
older reported a past year opioid misuse. Of these, 8% used heroin 
and 92% reported pain reliever misuse only. 
Past Year Opioid Misuse 
Source: NSDUH, 2016
11 .5 Million People 
with Past Year 
Pain Reliever Misuse 
(97.4% of Opioid Misusers) 
10.9 MIiiion People with 
Pain Reliever Misuse Only 
(92.0% of Opioid Misusers) 
641 ,000 People with 948,000 People 
Past Year Pain Reliever Misuse with Past Year 
and Heroin Use Heroin Use 
(5.4% of Opioid Misusers) (8.0% of Opioid Misusers) 
/ 
307,000 People 
with Heroin Use Only 
(2.6% of Opioid Misusers) 
11 .8 Million People Aped 12 or Older with Past Year Opioid Misuse 
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Overdose rates and deaths have risen sharply in the past few 
years. Data from the Healthcare Costs and Utilization Project 
(HCUP) supported from the Agency for Healthcare Research and 
Quality (AHRQ) demonstrate that the national rate of emergency 
department (ED) visits and inpatient stays for opioid use is going 
up every year. Below are data derived from 30 participating states 
depicting this escalation, with the State of New York exceeding the 
national rates.
National Rate per 100,000 
Population of Opioid Related ED Visits
2005-2014
I expect that the numbers will be much higher when new data 
comes out. 
Abbreviation: ED, emergency department
Source: Weiss et al., 2006
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The following maps are very telling. They depict the rate of 
overdose deaths in the entire United States in 1999 compared to 
2015. In 1999, the hot spots, or areas representing 26-28 deaths 
per 100,000 individuals, were limited to Appalachian Valley and a 
small county in New Mexico.
Fast forward to 2015, and the signs are more ominous. The number 
of overdose deaths increase nationwide with large hot spots in 
New England, Ohio and the Appalachian Valley and the southwest. 
People are literally dying every day, often in their youth. 
Source: CDC/NCHS, National Vital Statistics System. Designed by L. 
Rossen, B. Bastain & Y Chong
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The Faces of Addiction
What do the faces of addiction look like? In 2016, David Armstrong, 
a senior enterprise reporter at STAT, owned by the Boston Globe, 
published an article entitled “52 weeks, 52 faces: Obituaries 
narrate lives lost to the opioid epidemic.” (Armstrong, 2016). To 
write this story, Armstrong searched Legacy.com and other sources 
to find obituaries of people who died after a struggle with opioid 
addiction. One may note that this sample may be biased as the 
information is derived from written obituaries, which may say 
something about the families’ resources and education. However, it 
does reflect that opioid addiction is prevalent in white populations. 
These stories are very compelling, and most everyone can identify 
or connect with an entry. We have a 27-year-old fitness buff from 
Source: CDC/NCHS, National Vital Statistics System. Designed by L. 
Rossen, B. Bastain & Y Chong
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Norwich, Connecticut; a 32-year-old father of two from Cleveland, 
Ohio; a 27-year-old, who was one of nine children, from Tolland, 
Connecticut; a 52-year-old grandmother from Mansfield, Ohio; 
and so on. What this shows you is that these are people within 
communities, people that you could know, and people whose lives 
were shortened unnecessarily.
Words Matter
One of the themes that I will repeatedly emphasize is that words 
matter. If you remember nothing else today, please remember that 
we can all help combat this public health crisis if we use accurate, 
less stigmatizing words when talking about addiction. When 
individuals feel stigmatized, they are less likely to seek treatment. 
They feel ashamed, and this presents an unnecessary barrier to 
care. 
Source: Armstrong, 2016
Obituaries narrate lives lost to the opioid epidemic 
11),DAV ID ARMSTRONG 
Michael T. Brandon (Feb. 21) 
Fitness buff 
JVorwich, Connecticut 
DavidNff111tongX / DECEMBER 20, aou; 
Alex Thomas Zimmer (July 23) 
James R. Gimenez (Sept. 16) 
32yearsold 
Father of two 
Cleveland, Ohio 
THE FACES OF ADDICTION 
24years old 
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Instead of calling a person with an addiction an “addict,” we can use 
words such as a person with an “opioid use disorder, or addiction.” 
Thus, the person is not defined as his or her disease. We do not refer 
to individuals with diabetes as that “diabetic over there.” We are 
trying very hard to educate journalists and the public to talk about 
addiction as a disease. Even though many patients call themselves 
addicts, we try as physicians to say, “You may call yourself an addict, 
but I’m not going to refer to you like that. You have an opioid use 
disorder, and I am going to help you treat that.” 
Using accurate words also matters. Often the media is not accurate. 
For example, I recently read a post from a New York Times article 
that calls a “typical overdose” when a doctor prescribes legally, but 
someone other than intended digests the pills. While this was an 
important past issue, currently the typical overdose is caused from 
the use of heroin or synthetic opioids such as fentanyl. Similarly, 
news articles have spoken about the “addicted baby.”  This is 
impossible, as a baby does not display behaviors such as going 
out of their way to seek opioids despite known consequences, 
spending all their time seeking opioids and impairing relationships, 
etc. Accurately stated, we have babies that suffer from opioid 
abstinence syndrome. Recently, my colleagues and I at Yale have 
been working with journalists and the news media to make sure 
that the information they’re putting out there is accurate and less 
stigmatizing.
What is Addiction?
Addiction is a Disease 
Addiction is not a moral failing, it is a chronic relapsing disease. 
Robert DuPont, who was the first director of the National Institute 
on Drug Abuse (NIDA), once told a story that I found very compelling. 
He describes a scenario imagining that you are driving a car in a 
residential zone at a fast speed and a child runs in front of you. 
Gail D’Onofrio
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You know you need to stop or you’re going to seriously hurt, if 
not kill, that child. You try desperately to stop, but you can’t, the 
brakes don’t work. You cannot will the breaks to work, just as one 
cannot will themselves out of this disease. Similarly, one cannot will 
themselves out of diabetes, cancer, or heart disease. 
Addiction has potential genetic, environmental, and behavioral 
components. There are profound neurobiological changes that 
occur when transitioning from opioid use to an opioid use disorder. 
The brain is comprised of many areas and neuro circuits that you 
see below. 
Addiction is thought to, in some way, “hijack” the reward system, 
which is mediated through dopamine as a neurotransmitter. Our 
reward system is very powerful. It is important for our individual 
survival; we need to eat and drink as well to procreate and survive 
as a species. When an individual uses heroin they experience an 
overwhelming pleasurable response. At some point the reward 
Source: NIDA, 2007
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system overpowers the individual’s ability to resist that feeling. 
Heroin also affects the prefrontal cortex, which controls our 
judgement. Thus, one will seek to use the drug no matter what 
the consequences. Why this happens in some individuals and not 
others, and why some individuals can use a drug without crossing 
over to an addiction is not entirely known. 
Chronic Pain vs. Experimental Use (Noble, et al., 2010; Shaheed, et 
al., 2016)
It is important to understand the intersection between chronic 
pain, opioid use disorder, and experimental use. Both chronic pain 
and experimental use can lead to opioid use disorder, but there 
are big differences between these groups. Chronic pain affects over 
100 million people, or one in three individuals. Twenty-five million 
Americans suffer from daily pain, and 40 million from very severe 
chronic pain, with costs over $600 billion every year attributable 
to treatment costs, lost wages, and productivity. Thus, we need to 
find alternative ways to deal with pain, other than opioids. While 
individuals may become physically dependent on opioids for pain, 
such as someone with end stage cancer, there is a distinction 
with developing an addiction. This criteria for addiction entails 
continuing to use despite negative consequences, devoting an 
enormous amount of time and energy to obtaining the drug, and 
its interference with work and personal relationships. In addition, 
there are individuals who use these drugs experimentally at parties 
etc. Some of these people will use, live through it, and never 
develop an addiction. But some individuals will have their reward 
system so activated that they will develop an opioid use disorder. 
What is an addiction to opioids or an opioid use disorder? The 
Diagnostic and Statistical Manual (DSM-5) (American Psychiatric 
Association, 2013) for opioid use disorder consists of 11 questions. 
Depending on how many questions are positive, one can have a 
Gail D’Onofrio
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diagnosis of a mild, moderate, or severe opioid use disorder. The 
most prominent component of the disorder is this first thing on 
DSM’s list – taking opioids in really large amounts and for longer 
than intended. It is also when you are doing something you cannot 
stop, no matter what you try to do, you can’t stop taking it. You could 
lose your family, you could lose your job, you could lose everyone 
that was significant to you, but it really wouldn’t matter. You’re still 
going to use more of it. And you will stop doing other things that 
you used to do because you’ve spent all your time thinking about 
when you’re going to get your next drug. That is addiction. 
What addiction is not. The development of tolerance and the need 
for more medication to get the desired effect. For example, with 
sickle-cell disease, one will develop a tolerance and need more and 
more medication for pain relief through disease progression and 
repeated pain crises. In addition, as their body becomes physically 
dependent on the medication, they will experience withdrawal 
symptoms with abrupt cessation of their medication. This can also 
happen to individuals who have progressive cancer. This doesn’t 
mean that they have an addiction, because they’re being treated by 
physicians who are prescribing the medications as needed. 
What Does it Feel Like to Have an Opioid Use Disorder?
Contrary to what one may think, individuals with severe opioid 
use disorders are not high all day. They may get some relief from 
use, but then they experience large fluctuations from experiencing 
cravings and dysphoria, to some relief. While initially they may 
experience euphoria, with chronic use the euphoria becomes less 
and less and it becomes just a feeling of relief. 
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What does it Feel like to have Opioid Use Disorder?
  
Their life is consumed with not feeling poorly and avoidance of the 
horrific withdrawal symptoms. Thus, they are constantly looking for 
their next drug. Withdrawal causes irritability, restlessness, nausea, 
abdominal pains, and achiness, perhaps the worst flu symptoms 
you can imagine. 
Fentanyl and Overdoses 
Many overdose deaths are now from synthetic opioids such as 
fentanyl. The question is, why is so much fentanyl reaching the 
market? One answer is that fentanyl is purely synthetic, meaning 
it is manufactured in a laboratory. It is relatively easy to make and 
it is cheap. Additionally, a lot of fentanyl is brought in from China, 
Central America, and South America. So, you can sell fentanyl for 
almost the same price as heroin, but since it’s cheaper to make, 
you make ten times or twenty times more money. This is scary. 
We are seeing so much in circulation and it is so powerful that it 
can kill an individual the first time they try it. People may not even 
know that what they buy or use is fentanyl. They may think they 
Source: Dole, Nyswander, and Krock, 1966





are using cocaine or heroin, but actually they are using something 
that’s much more powerful. In New Haven, Connecticut we had an 
unfortunate experience with 18 overdoses detected in a few hours 
that resulted in multiple deaths. These individuals were snorting 
a white powder they thought was cocaine, but in reality, it was 
fentanyl (Tomassoni et al., 2017). In addition, counterfeit pills are in 
circulation and available from the internet that look like an opioid 
such as Oxycodone or Percocet, when in fact they are fentanyl. Most 
likely the general public will not be able to distinguish between a 
real and a counterfeit pill. 
The overdose data is always behind, as the CDC reports annually 
on the previous year. Unfortunately, we suspect that the 2016 data 
will reveal at least 65,000 overdose deaths, and it is estimated to 
be around 100,000 in a few years if we continue on the same pace. 
Source: Katz, 2017
U.S. Drug Deaths Climbing 
Faster Than Ever 
59,000 to 65,000 
deaths per year 
2016 
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The Impact of Opioids on Certain Populations
Adolescents are misusing opioids more than they did before. 
Adolescent overdose rates have gone up from 1.6 to 3.7 per 100,000 
(Curtin et al., 2017). This tells us that that it is important to start 
young with prevention. 
Women are particularly affected by opioid misuse as well. Women 
become dependent more quickly and use it differently. They tend 
to take smaller amounts for shorter periods of time, which usually 
makes you more dependent. Women are also more sensitive to 
cravings. 
Older people are also misusing opioids and that, in combination 
with chronic diseases, other medications, and co-prescribing, 
makes it more difficult to stop overdoses. According to the 2014 
NSDUH, opioid use among adults 50 and older has increased from 
1% to 2%. One reason may be that while new cancer therapies are 
helping many live longer, these individuals are often prescribed 
opioids to manage pain. Now, the palliative care team are asking 
for help because their patients are living longer than they thought 
and are now physically dependent on this medicine. 
What Led to this Crisis?
The First Epidemic
We have known about opium since Hippocrates in 400 BC. In 1803 
a German pharmacist extracted morphine from opium and called 
it Morpheus for the Greek god of dreams. It was right around 
this time that we began to have our first epidemic. At the time, 
it was considered one of the most useful drugs in the world and 
in the physician’s arsenal. However, it apparently tasted very 
badly and was associated with many gastrointestinal symptoms. 
The development of the hypodermic needle in 1853 allowed for 
immediate use in acute pain without these negative side effects. 
The advent of the hypodermic needle and intravenous morphine 
Gail D’Onofrio
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administration during the Crimean War and the U.S. Civil War, 
allowed for the immediate treatment of acute injuries on the 
battlefield; but unfortunately, 400-plus soldiers were left with what 
was termed “soldier’s disease,” which in reality was an opiate use 
disorder. 
As the 1800’s continued, addiction became very widespread. 
In 1898, Bayer, well known for discovering aspirin, patented 
heroin as an improvement over morphine. The use of heroin was 
pharmaceutically driven and physicians and pharmacists used it for 
everything. Without any scientific knowledge or regulation, heroin 
was touted as the best thing for all ailments. People were given it 
for everything. Housewives, in particular, developed an addiction 
because they were given it often for menstrual cramps, anxiety, or 
headaches. 
Eventually, the lack of regulation of heroin became evident and in 
the early 1900’s. Teddy Roosevelt, with the assistance of a physician 
from Ohio, established an opiate commission to begin to develop 
regulations. The opiate commission established the Harrison Narcotic 
Act, designating morphine a controlled substance. The Food and 
Drug Administration (FDA) proclaimed that manufacturers could no 
longer add opium and heroin indiscriminately to other substances 
and medications. After the Harrison Narcotic Act, regulations were 
established regarding indications for the use of opiates such as 
heroin and morphine and their distribution. Fortunately, at that 
time, there was not a large, lucrative, underground crime network 
complicating the expansion of nonprescribed opiates, thus the 
epidemic was contained with improved physician knowledge and 
the establishment of government regulation. 
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The Second Epidemic
The second epidemic was not as big as the first, when opioids were 
widespread throughout the U.S., though equally pharmaceutically 
driven. In the 1950’s Purdue Pharma was bought by two brothers 
who were physicians from New York, Raymond and Mortimer 
Sackler. With little data to support the use of OxyContin for pain, 
and its supposed lack of addictive potential, they developed and 
marketed the drug widely 1996. Pioneers of academic detailing, the 
brothers sent pharmaceutical representatives to doctors’ offices 
and advertised extensively in an attempt to increase their sales 
with over 1 billion reported in 2000. 
Another major cause of the second epidemic was a combination of 
many soldiers coming back from Vietnam and having widespread 
domestic proliferation of heroin on the black market. During this 
time, heroin injections became the leading cause of death in New 
York City. As a response, methadone clinics were introduced to 
treat heroin addiction, which were successful. In addition, in 1971, 
we started “the war on drugs”, which we eventually learned did 
not work. Consequently, a lot of individuals with addictions were 
incarcerated, without treatment or prevention strategies in place. 
The Current Epidemic
In the 1990’s we recognized that pain was poorly treated. As 
resident physicians, we were told that we did not give out enough 
pain medicine, and we were scripted to say to patients in pain “I 
have more pain medicine than you have pain.” In 1996 pain became 
the fifth vital sign. In addition to the original four primary vital signs 
that indicate the status of the body’s vital functions including body 
temperature, heart rate, blood pressure, respiratory rate, we were 
required to ask about pain. 
Gail D’Onofrio
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We would show patients the pain measurement scale below. 
In 2001, the Joint Commission, a non-profit that accredits hospitals 
and other U.S. healthcare organizations, set pain management 
standards, and we were required to provide pain medicine for 
anyone that chose a four or more on this scale. But, as we all know, 
pain is very subjective. 
We could start with ibuprofen or Tylenol, but if that didn’t work, we 
were expected to give them something stronger. To make matters 
worse, the Centers for Medicare and Medicaid Services (CMS) linked 
our reimbursements with our patient satisfaction. Many emergency 
departments throughout the country pay their physicians based 
on their patient satisfaction scores. Consequently, many doctors 
started overprescribing pain pills to improve their scores. 
The combination of all these events, pharmaceutical influence, 
pain guidelines, and patient satisfaction scores dictating “so 
called quality” and physician reimbursement created a perfect 
storm. Today, two out of three people in this country get a pain 
pill prescription every single year. Below, you can see the standard 
doses of opioids per million. Americans by far consume most of the 
opiates in the world and use 99% of the world’s hydrocodone.
PAIN MEASUREMENT SCALE 
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Standard Daily Doses of Opioids per Million Inhabitants
Opioid Agonist Treatment
An individual with an opioid use disorder (OUD) experiences severe 
swings during the day from acute dysphoria or withdrawal and non-
dysphoric episodes. After use of opioids for long periods they no 
longer experience the “high” but fluctuate between these states. 
An opioid agonist, such as methadone and buprenorphine, can 
stabilize how an individual with OUD feels throughout the day, and 
allows one to function at home and work. Opioid agonist treatment 
is a very effective. We call it Medication-Assisted Treatment (MAT). 
Many believe this is an inaccurate statement and may contribute to 
more stigma. For example, we don’t call the treatment for diabetes, 
Source: United Nations International Narcotics Control Board, March 
2017
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i.e. insulin, medication assisted treatment. It is the treatment of 
diabetes. Thus, a more appropriate term may be medication for 
addiction treatment, which would preserve the acronym MAT. 
We know that MAT works from multiple studies. Baltimore 
Maryland has had a huge problem with heroin overdose deaths. 
From 1995-2009, Baltimore expanded the use of buprenorphine 
and methadone as part of their opioid agonist treatment, and as 
you can see in the graph below, the number of deaths markedly 
decreased with the expansion of methadone treatment programs 
and the ability of physicians to prescribe buprenorphine in 2002. 
Heroin OD Deaths during Expansion of Methadone & 
Buprenorphine in Baltimore, 1995-2009
We have also seen examples of this happening in Sweden and 
France. Recently, in the British Medical Journal, a major analysis of 
multiple studies demonstrated that use of MAT prevents overdoses, 
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One question frequently asked regarding Opioid Agonist Treatment 
is whether patients need counseling in addition to medication. 
A large Cochrane review that was recently published included a 
systematic review of 34 randomized clinical trials with 3,777 patients 
receiving buprenorphine or methadone with basic versus additional 
structured counseling (Mattick et al., 2014). They concluded “the 
present evidence suggests that adding psychosocial support does 
not change the effectiveness of retention in treatment and opioid 
use during treatment.” It seems intuitive that, what I like to call “life 
coaching,” can be added because we do need these individuals to 
be an active part of our society, to work and be viable members of 
the community. Thus, education, obtaining GEDs, or making sure 
individuals have adequate housing is all necessary for maintaining 
recovery. And we know that often individuals with opioid use 
disorder have co-existing mental illness, and these conditions need 
to be adequately treated. But, an essential aspect of treatment is 
medication or MAT, specifically opioid agonist treatment. 
Advantages of Opioid Agonist Treatment
Opioid Agonist Treatment reduces withdrawal symptoms, cravings 
and illicit drug use. It also reduces transmission of hepatitis, HIV, 
and complications from IV drug use such as skin infections and 
abscesses. It reduces overdose, death, and other risky behavior such 
as high risk sexual behavior without adequate protection. MAT also 
reduces legal consequences and crime. Finally, it allows individuals 
to sustain relationships and find meaningful employment. MAT 
also makes good economic sense. Every dollar spent on addiction 
treatment yields a return of $4.00-$7.00 in reduced drug-related 
activities such as crime, criminal justice costs, and theft. The total 
savings to healthcare exceed costs by a ratio of 12:1, from data 
reported in 2012. 
Gail D’Onofrio
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Without adequate treatment, more people are going to die. 2015 
was the first year in recent history that life expectancy in the U.S. 
fell, primarily in the white male population due to the surge in 
fatal opioid overdose deaths (Rudd et al., 2016). MAT is endorsed 
by almost every agency you can think of - the World Health 
Organization, the National Institute of Health (NIH), the National 
Governor’s Association, the Surgeon General, the Office of National 
Drug Control Policy, and the Substance Abuse and Mental Health 
Services Administration (SAMHSA). 
Limited Access to Opioid Agonist Treatment
In a special report in The New England Journal of Medicine, Dr. Nora 
Volkow, director of the National Institute on Drug Abuse (NIDA) 
and Dr. Francis Collins, director of National Institutes of Health, 
say “These medications coupled with psychosocial support are the 
current standard of care for reducing illicit opioid use, relapse risk, 
and overdoses, while improving social function. However, limited 
access to providers and programs can create barriers to treatment.” 
(Volkow and Collins, 2017). Even with all this knowledge and 
evidence, only a third of drug treatment centers use MAT (SAMHSA 
TED, 2013 & Knudsen, Abraham, & Roman, 2011). This means 
that a lot of the time, patients come out of abstinence based 
rehabilitation programs and they end up dying. We know that 
release from any controlled abstinence environment, be it a drug 
program or incarceration, is a major risk factor for overdose and 
death. This results from the individual becoming less tolerant, and 
with relapse they overdose. 
A study published last year in The Journal of the American Medical 
Association examined the medications provided before and after 
an opioid overdose event from 2008-2013 in the Pennsylvania 
Medicaid system. Unfortunately, very few of these people were 
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ever prescribed medication treatment for opioid use disorder after 
they overdosed. In addition, there was little reduction in the opioids 
they were prescribed! (Frazier, Winfred, et al., 2017).
So, moving forward, we have clear evidence that we need to fund 
treatment and promote behavioral health parity so that people have 
access to this treatment. The Urban Institute recently published a 
study titled, “Rapid Growth in Medicaid Spending on Medications 
to Treat Opioid Use Disorders and Overdose,” which looked at the 
rapid growth in Medicaid spending on medications to treat opioid 
use disorder and prevent overdose (Clemans-Cope et al., 2017). 
The next graph depicts the medications used to treat opioid use 
disorder, and the money spent on these medications over the years. 
The spending is increasing and this is a good thing.
Source: Frazier, Winfred, et al., 2017
Medication Patterns Before and After Heroin or Opioid Overdose Events, 2008-2013 
Heroin Overdose n=2068) Prescription Opioid Overdose(n=3945) 
Characteristics 
Before overdose After overdose Before overdose After overdose 
% % % % 
Any prescription 43.2 39.7 66.1 59.6 opioid use 
Prescription opioid 10.5 9.0 32.4 28.3 duration > 90d 
Any medication-assisted 29.4 33.0 13.5 15.1 
treatment 
Buprenorphine 19.2 20.3 5.4 6.7 
Methadone 10.4 12.6 8.2 8.3 
Naltrexone 2.4 3.0 0.4 0.8 
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Medicaid Spending on Buprenorphine, Naltrexone, and Naloxone 
Prescriptions for OUD
The following graph looks at Medicaid spending for states with and 
without Medicaid expansion. If you were in an expanded state, the 
money spent is increasing and people are accessing medications. 
Unfortunately, if you were in a non-expansion or a late expansion 
state, money was not being allocated for effective treatment. The 
bottom line is, we need to make sure that everyone who needs 
these medications for treatment has access to them.
Source: Clemans-Cope et al., 2017
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Medicaid Spending on Buprenorphine, Naltrexone, and Naloxone 
Prescriptions for OUD, by State
Connecticut Opioid Response (CORE)
The Connecticut Opioid REsponse (CORE) was created as part of 
Governor Dannel Malloy’s strategic initiative to reduce overdose 
deaths. A group of Yale University Professors led by Dr. David 
Fiellin, including myself, Dr. William Becker, and Dr. Robert Heimer 
partnered with many agencies and organizations within the state 
to develop this plan. Our goal to reduce deaths included six specific 
strategies, including increasing access to MAT, reducing OD risk, 
safe prescribing, increasing access to Naloxone, data sharing, and 
reducing stigma. 
Source: Clemans-Cope et al., 2017
Millions of dollars 



















Reduce the Risk of Overdose
We needed to educate the medical community and the public 
regarding those at highest risk for overdose. This includes those 
with a prior non-fatal opioid overdose; leaving a controlled settings 
such as residential treatments, detoxification or incarceration who 
have lowered opioid tolerance; those prescribed doses of opioid 
analgesic greater than 90 milligram morphine equivalents (MME) 
per day; those who are co-prescribing or co-using opioids and 
benzodiazepines or injecting opioids; those with exposure to high 
potency opioids (fentanyl, W-18), low levels of physical tolerance 
(new initiates); and those with sleep disordered breathing such as 
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Safe Prescribing 
All states in the U.S., except for Missouri, have prescription 
monitoring programs (PMP). Most states require that a physician 
reviews the program if writing an opioid prescription for more 
than 72 hours to assess if other providers are prescribing opioids 
or other narcotics. This alone is not a panacea, as individuals who 
are buying illicit drugs are obviously not in the system. However, 
the PMP is associated with less deaths. There were an estimated 
600 fewer overdoses nationwide in 2016 with the implementation 
of this program, so there is value to accessing the system (Patrick, 
Fry, et al., 2016).
The CDC also published guidelines for doctors who prescribe 
opioids. Two recent articles highlight the importance of prescribing 
short courses of opioids when necessary. A recent article in 
Morbidity and Mortality Weekly reported the characteristics of 
initial prescription episodes and the likelihood of long-term opioid 
use in a sample of patients (2006-2015) derived from the IMS 
Lifelink+ database (commercially insured population). The authors 
found that prescribing three days or less of opioids, often sufficient 
for most acute pain, was associated with a relatively low long-term 
rate of opioid use (6%). This rate of long-term use significantly 
increased to 13.5% for persons whose first episode of use was for > 
8 days and to 29.9% when the first episode of use was for > 31 days 
(Dowell, Haegerich & Chou, 2016). 
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One- And 3-Year Probabilities of Continued Opioid Use Among 
Opioid-Naïve Patients, 
By Number of Days’ Supply* of the First Opioid Prescription — 
United States, 2006–2015
Another paper published in the New England Journal in 2017 
investigated whether overuse of opioids may be driven in part 
by physician prescribing. Researchers performed a retrospective 
analysis involving Medicare patients who had an index ED visit from 
2008-2011. Emergency physicians within a hospital were categorized 
as being high-intensity or low-intensity opioid prescribing according 
to quartiles of prescribing rates within the same hospital. They then 
compared rates of long-term opioid use (defined as 6 months of 
days supplied) in the 12 months post ED visited among patients 
treated by high-intensity or low-intensity prescribers. They found 
a wide variation in rates of opioid prescribing existed among MDs 
practicing in the same ED. Long-term opioid use at 12 months was 


















0 5 10 15 20 25 30 35 40 45 
Days' supply of first opioid prescription 
* Days' supply of the first prescription is expressed in days (1-40) in 1-day 
increments. If a patient had multiple prescriptions on the fi rst day, the 
prescription with the longest days'supply was considered the first prescription. 
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significantly higher among patients treated by the high-intensity 
prescribers (adjusted odds ratio, 1.3; 95% CI 1.23 to 1.37; p<0.001) 
(Barnett, Olenski, et al., 2017).
So, we have pretty good evidence that we need to prescribe less 
and more judiciously. We have to recognize that we may be part of 
the problem. 
Increase Access to Naloxone (Narcan)
Naloxone is an opioid agonist and its use is a life-saving intervention. 
The medication can be administered intravenously, in a nasal 
spray (ADAPT), or is available in an atomizer form, which must be 
assembled and is more challenging in an emergency. We know that 
having naloxone available to individuals with an opioid use disorder 
and their family or community can be life- saving. Personally, I 
believe this should be available in any public place, for example in 
an automatic defibrillator, along with an EpiPen. We need them in 
airplanes, churches, coffee houses, any place that people gather. 
There are Good Samaritan overdose immunity laws in many states. 
These laws protect a person if you are using with someone and 
that person overdoses. With these laws in place, you can call 911, 
administer naloxone, and you will have immunity from arrest if first 
responders or police find you with drug paraphernalia. 
Data Sharing
Data sharing is essential if a community is to have timely information 
regarding surveillance of use, overdose, treatment availability, 
etc. States such as Massachusetts and Maryland (Baltimore) have 
assembled comprehensive strategic plans, and they have shared 
data with insights. However, it continues to be a challenge within 
and among states. In Connecticut, Governor Malloy signed into law 
a legislation package that said we could data share between state 
agencies regarding opioid misuse and opioid overdose deaths. 
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This law allows us to obtain data so we can map out hot spots of 
overdose and use, and determine whether these individuals were 
or are currently in treatment, have visited an ED, etc. 
Reduce the Stigma
Another major initiative that the CORE team is focused on is reducing 
the stigma of having an opioid disorder, which brings us back to 
where we started, that words have power. This is something that 
we just need to keep talking about. We hosted a media roundtable 
at Yale University and we talked about laypeople’s views and 
increasing community understanding of opioid use disorder and 
treatment. We want to let people know that language is powerful, 
especially when talking about substance use disorders. So, we’d like 
you to avoid certain terms and replace them with other language 
instead. Stigma may place an unnecessary barrier between need 
and treatment and we are working hard to reduce its impact. 
When Discussing Addictions ... 
Avoid These Terms: 
Addict, user, drug abuser, 
junkie 
Addicted baby 




Clean or dirty urine test 





Use These Instead: 
Person/Patient with 
opioid use disorder or 
opioid addiction 
Baby born with neonatal 
abstinence syndrome 
Opioid use disorder 
Disease 
Drug addiction 
Negative or positive urine drug 
test 
Opioid agonist treatment 
Medication for Addiction 
Treatment 
Return to use/ Setback 
Treatment attempt 
Being in remission or recovery 
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Language is important, so we should be saying “a person with 
an addiction” or “a person with an opiate use disorder” instead 
of “an addict” or “a junkie.” Instead of “opiate abuse” or “opiate 
dependence,” we’d like to talk more about “opioid use disorder.” 
We avoid the term “opioid substitution” or “replacement therapy,” 
because it is not substituting one drug for another. It’s a medication, 
whether it’s buprenorphine or methadone, and it is given in 
prescribed doses under a doctor’s supervision. Using this language 
can be hard, even for me, but it is essential if we are going to change 
the climate and avoid contributing to the stigma that surrounds this 
disease. 
What are Solutions to the Opioid Epidemic?
One thing we know about this epidemic is that arrests and use of 
the judicial system does not work. We’ve already tried this and our 
jails are full of individuals with substance use disorders. The war on 
drugs only led to more and more people being incarcerated. The 
Court Appointed Special Advocates (CASA) reported data last year 
that 85% of the U.S. prison population either has an addiction or 
their lives were affected by substance use. 
Get People into Treatment
Despite how prevalent opioid addiction is, only one in five people 
get treatment. That is abhorrent. So, what are some things that I 
can do as an emergency physician? I can work on increasing access 
to treatment. Why the emergency department? We are the front 
door of the hospital, and we are where the patients are. A famous 
bank robber was once asked, “Why do you rob banks?” and his 
answer was, “I rob banks because that’s where the money is.” The 
emergency department is where many receive their care, so why not 
use the ED visit as an opportunity to help? Sometimes people come 
in seeking treatment directly, or we see them for complications 
of injection use, such as skin infections, or they present with an 
overdose, or we identify their disease through screening. In any 
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case, we have the opportunity to intervene and engage them in 
treatment. 
So, my colleagues and 
I had this great idea. 
What if we could initiate 
treatment while these 
patients were in the ED? 
Many of these are young 
patients without other 
chronic diseases and 
primary care physicians. 
We thought, maybe we 
could initiate opioid 
agonist treatment with 
buprenorphine and help 
make this direct linkage 
to ongoing maintenance 
therapy. We shifted the 
paradigm and started treating opioid disorder like any other disease 
or emergency in the case of overdose - and we could do that with 
buprenorphine, a medication that physicians have been capable of 
using since 2002. 
Buprenorphine is a partial agonist, which means it has a ceiling 
effect, and after a certain dose its effect levels off. It has a very 
high affinitive to the receptors in the brain. Unlike buprenorphine, 
methadone is a pure agonist. The effect continues as the dose rises 
and it can therefore be lethal. Naloxone is an antagonist, not to 
be confused with naltrexone, which you may hear about regarding 
treatment. Naloxone is not treatment, but the antidote to overdose, 
precipitating withdrawal. So, buprenorphine is an ideal medication 
to initiate in the ED. It is often combined with naloxone to prevent 
diversion. When taken sublingually it is absorbed and effective. 
Source: The National Alliance of 
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Unfortunately, in order to prescribe buprenorphine (often known 
as Suboxone) a physician must obtain an X waiver from the Drug 
Enforcement Administration (DEA). This process includes four hours 
of online training and an additional four hours of in person training, 
and this is often a barrier for physician prescribing. You may find this 
very ironic since any physician can prescribe thousands of opioid 
pills such as OxyContin and oxycodone, but we need an eight hour 
course to treat opioid use disorders. Fortunately, there is a 72-hour 
rule [Title 21, Code of Federal Regulations, Part 1306.07(b)] that 
allows physicians to administer (but not prescribe) narcotic drugs 
for the purpose of relieving acute withdrawal symptoms, while 
arranging for the patient’s referral for treatment. According to this 
rule, no more than one day of medication may be administered 
or given to a patient at one time. The patient must return to the 
ED each day, for no more than 72 hours, and this period cannot 
be renewed or extended. This can work well, but one limitation is 
that the emergency physician has arranged someplace to send the 
patient for ongoing care. 
My colleagues and I conducted a study to compare the efficacy of 
three intervention methods for opioid dependent ED patients. 329 
patients were enrolled in this study from April 2009-June 2013. Our 
question was “How should we treat them?” One intervention was 
just referring them. These referrals were more than your typical 
referral – a list of local providers and programs were provided based 
on the patient’s insurance and preference. The second arm involved 
a brief psychosocial intervention, namely the Brief Negotiation 
Interview or BNI, where our goal was to motivate them to accept 
treatment. The brief intervention was followed by a facilitated 
referral. We contacted the program, arranged transportation if 
necessary, and in some cases even received clearance through 
insurance companies to get people into treatment. The third arm 
of this study, included the BNI plus ED-initiated buprenorphine, 
either administered in the ED or given as a take home dose if the 
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patient was not in sufficient withdrawal to initiate treatment at the 
time of the ED visit. A sufficient supply was given to take home for 
at most 72 hours when they received an appointment for follow 
up in our primary care center, where treatment was continued for 
10 weeks. Our primary outcome was treatment engagement at 30 
days. We found that almost 80% in the ED-initiated buprenorphine 
group were in a formal treatment program at 30 days compared 
with brief intervention or referral (see below). 
Engaged in Treatment at 30-Days
We also found that in our buprenorphine group, there were few 
with inpatient treatment compared to the others, which is of course 
very cost-effective.
We also performed a cost-effective analysis (Busch, 2017) and 
found out that willingness to pay for every dollar, whether it was 
for treatment engagement or whether it was for one day free of 
opiates, for every dollar, buprenorphine proved to be more cost 
effective. Thus, our mantra that “we need more chairs, not beds” 
for the treatment of opioid use disorder. You really don’t need 
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inpatient stays for this. You need the medication. We concluded that 
with ED-initiated buprenorphine treatment and follow-up in our 
primary care, we improved engagement in treatment; decreased 
people’s illicit use; and reduced inpatient services; all while being 
cost-effective. 
How Do We Apply this to the Real World and Move Forward? 
(Sharfstein, 2017)
Here is an example of a real patient that was pulled out of a vehicle 
unresponsive. Her oxygen was very low. She was given naloxone 
and after she woke up she said she had just switched over from 
prescription drugs to IV heroin. Why should this case be treated 
differently than other emergencies? We resuscitate people all the 
time, and we do it in a very specific way. Patients who are about 
to die receive urgent propriety in ED care, for example, patients 
who have had a stroke or myocardial infarctions (MI). For MI and 
stroke, we know we have a certain amount of time to get them 
to definitive treatment, and we have created specific quality 
measures, such as time from door to EKG, EKG to the catherization 
laboratory, and time to opening the culprit lesion. In stroke, we 
have door to needle (medication administration) time. We don’t 
hand out a pamphlet and say, “You’re having a big heart attack, but 
it’s Friday, so I’m going to give you this pamphlet and you can go 
out and find a cardiologist and laboratory to open up that coronary 
artery for you. But with your insurance I don’t think you’re going to 
find somebody over the weekend. See you later, and good luck.” In 
the past, that’s exactly what we have done for patients who present 
with an overdose or signs and symptoms of opioid use disorder 
that we know are at high risk for overdose. They came in, they may 
have even been dead at the time, we revived them, we observed 
them for a while, and we get them out of the ED in a couple hours. 
What we’re trying to present as best practice now, is to observe 
these patients and start treatment when appropriate. Let’s start to 
engage them in this conversation. Even if they didn’t come in for an 
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overdose, but we know they’re going to die from a variety of other 
issues, let’s still try to engage them and give them a facilitated 
referral. Then, let’s engage them in harm reduction strategies such 
as overdose education and naloxone distribution. If we did all of 
this, we could really save lives. We now have several emergency 
physicians leading this charge throughout the country, not only in 
Connecticut. We have Dr. Sullivan, who has started his own clinic 
in Syracuse, New York, Dr. Herring in Oakland, California, and two 
ED physicians in Camden, New Jersey working at Cooper Hospital. 
These are the real heroes. They saw a problem and stepped up to 
the plate, against all odds, to do something about it. 
Conclusion
The opioid crisis is escalating. Lives are being wasted every day. 
We have the opportunity to change this, adapting evidence 
based therapies and developing state wide strategies that focus 
on increasing access to MAT, identifying high risk individuals, safe 
prescribing, offering harm reduction strategies, sharing data and 
decreasing stigma. Most of all, we hope to change three keys about 
addiction: the way we think about it, the way we talk about it, and 
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